Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial

Trial Profile

The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms IMPROVE
  • Sponsors Roche
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Planned end date changed from 1 Jul 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top